Trial Profile
A single dose study of R1450 in patients with Alzheimer disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Feb 2010
Price :
$35
*
At a glance
- Drugs Gantenerumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Roche
- 08 Dec 2008 Status changed from active, no longer recruiting to completed.
- 11 Jan 2008 Status changed from recruiting to in progress.
- 01 Nov 2006 New trial record.